Pre-clinical results from DEP-HER2 ADC in 2015.
"We are very excited by these latest results for our targeted DEP ™ conjugates and feedback from commercial parties on this new data has been very positive indeed. Discussions are now underway with a number of pharmaceutical companies in relation to this targeted DEP conjugate …”
Meanwhile, almost 9 years later ….
Ann: DEP outperforms leading treatments in ovarian cancer model, page-8
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.001(1.02%) |
Mkt cap ! $40.48M | |||
| Open | High | Low | Value | Volume |
| 9.6¢ | 10.0¢ | 9.6¢ | $5.703K | 58.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 20000 | 1 |
View Market Depth
| Last trade - 15.41pm 11/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |